Psychedelic effects are mediated by 5-HT2A receptor mechanisms
the verdict
SUPPORTED
the evidence backs this
confidence 81/100
Extensive scientific literature consistently demonstrates that the behavioral, perceptual, and neuroplastic effects of classical psychedelics are primarily mediated by agonism at the serotonin 5-HT2A receptor.
Evidence for · 10
Psychedelic 5-HT2A receptor agonism: neuronal signatures and altered neurovascular coupling.
2023 · cited by 9
Paper 0 notes that psychedelic-induced neuroimaging and functional changes are dependent on 5-HT2A receptor agonism.
See more details
More for · 9
Biased Signaling in Psychedelic Action.
2026 · cited by 3
Paper 1 states that activation of the serotonin 5-HT2A receptor is critical for the psychopharmacological effects of psychedelics.
Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics.
2026 · cited by 0
Paper 2 reports that the beneficial effects of psychedelics are largely attributed to serotonin 2A receptor activation.
Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration.
2026 · cited by 0
Paper 4 notes that psilocybin acts primarily as a 5-HT2A receptor agonist mediating its downstream therapeutic effects.
Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action.
2026 · cited by 0
Paper 5 identifies serotonergic modulation via the 5-HT2A receptor as a key putative mechanism for psychedelic action.
Psychedelics and the quantum brain: a falsifiable hypothesis on Posner molecules and spin-dependent pharmacology.
2026 · cited by 0
Paper 6 states that classical psychedelics alter perception and neuroplasticity primarily via 5-HT2A receptor activation.
Psychedelics and Autism Therapy: A Review of Current Research and Future Directions.
2026 · cited by 0
Paper 8 mentions that psychedelics primarily modulate the serotonin 5-HT2A receptor to promote neuroplasticity.
Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging—From Depression to Neurodegeneration
2026 · cited by 0
Paper 9 specifies that psilocybin acts primarily as a 5-HT2A receptor agonist driving downstream signaling cascades.
Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy-<i>N</i>-methyl-<i>N</i>-isopropyltryptamine and Related Analogs.
2026 · cited by 0
Paper 10 notes that tryptamine psychedelics induce psychoactive effects via agonist actions at serotonin 2A receptors.
Psychedelic Therapy: A Primer for Primary Care Clinicians-Mescaline.
2026 · cited by 0
Paper 11 states that mescaline primarily exerts its psychoactive effects through serotonin-2A receptor agonism.